Business Context and Reporting Period
This Form 8-K Current Report was filed by Cyclacel Pharmaceuticals, Inc. on May 16, 2013. The filing reports the entry into a material definitive agreement regarding a public offering of common stock. The company is incorporated in Delaware and maintains its principal executive offices in Berkeley Heights, New Jersey.
Key Financial Metrics and Offering Details
- Offering Size: Up to 6,666,667 shares of common stock.
- Offering Price: $3.00 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 166,667 additional shares.
- Expected Net Proceeds: Approximately $18.5 million, or approximately $19.0 million if the over-allotment option is exercised in full.
- Expected Closing Date: May 21, 2013.
The filing does not provide historical revenue, profit, cash flow, margin, or debt figures. It focuses exclusively on the capital raise transaction.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with JMP Securities LLC as the representative of the underwriters. The offering is being made pursuant to an effective shelf registration statement on Form S-3 (Registration Nos. 333-187801). The agreement includes customary representations, warranties, indemnification obligations, and termination provisions.
Management Commentary, Risks, and Lock-Up Provisions
Subject to certain exceptions, the Company and all of its directors and executive officers have agreed to a lock-up provision. They are restricted from selling or transferring any shares of common stock for 90 days following May 16, 2013, without first obtaining the consent of JMP Securities LLC. The filing notes that the representations and warranties in the Underwriting Agreement were made solely for the benefit of the parties to that agreement and may be subject to limitations.
Investor Verification Checklist
- Verify the final closing date of the offering (expected May 21, 2013) and the actual net proceeds received.
- Confirm whether the underwriters exercised the 30-day over-allotment option to purchase the additional 166,667 shares.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific conditions to closing and indemnification details.
- Monitor the company's cash position post-closing to assess liquidity improvements relative to operational needs.